New Alzheimer’s drug donanemab ‘a step forward’ in dementia fight

A trial showing that the drug donanemab can slow Alzheimer’s disease has been hailed as a major development by Aussie experts.

The results of a trial showing that a new drug, donanemab, can slow the progression of symptoms of early Alzheimer’s disease has been hailed as “a step forward” by Australian dementia advocates.

The antibody medicine, from the US pharmaceutical giant Eli Lilly, helps in the early stages of the disease by clearing a type of protein called beta-amyloid that builds up in the brains of people with Alzheimer’s disease.

PET scans show an Alzheimer's sufferer with beta-amyloid build up.

According to data from a clinical trial released in the journal JAMA, the drug works rapidly and can clear nearly 90 per cent of amyloid plaque from the brain.

Removing the toxic protein in the early stages, slows the rate of cognitive decline, the research found.

Although not a cure, the results mean patients have more time to live independently before requiring care.

The research has also raised hopes that medicine may one day halt Alzheimers, which is the most common form of dementia.

Dementia Australia CEO Maree McCabe AM said donanemab was an exciting new development in treatments for dementia, which is the second leading cause of death of Australians, and the leading cause of death of Australian women.

Dementia Australia CEO Maree McCabe has welcomed the findings. Picture: NCA NewsWire / Daniel Pockett

“These results provide much needed hope for people who are developing symptoms, have mild cognitive impairment or who are in the early stages of Alzheimer’s disease,” Ms McCabe said.

Ms McCabe said the research highlighted the importance of early diagnosis so people could access treatment and support as soon as possible.

“We need to raise awareness and understanding of dementia to reduce discrimination and stigma so we can ensure people with concerns about their cognition are seeking information and support as early as possible.” she said.

“We know the earlier people access support and services the better their health, care and lifestyle outcomes.

“Donanemab will need to be approved by the Therapeutic Goods Administration (TGA) for use in Australia. It also comes with possible side effects that need to be carefully monitored by health professionals.”

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.